NCT01171651 - A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

February 28, 2013

Study Completion Date

December 31, 2015

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG

JX-594 followed by sorafenib

Patients will receive a total dose of 1e9 per treatment starting with one IV dose on Day 1 and injected intratumorally in 1-5 intrahepatic tumors on Day 8 and 22. Starting on Day 25 (3 days after the final JX-594 dose) patients will initiate oral sorafenib therapy twice daily according to standard approved guidelines. An optional maintenance JX-594 dose may be given intratumorally at Week 12 (sorafenib briefly interrupted).

Trial Locations (2)

Unknown

Pusan National University Hospital, Busan

Pusan National University Yangsan Hospital, Yangsan